<div id="readability-page-1"><p><span>Spero Therapeutics (NASDAQ:SPRO - Get Free Report)</span> was downgraded by stock analysts at Wall Street Zen from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report issued to clients and investors on Saturday.</p><div><p><span></span><span>Get <strong>Spero Therapeutics</strong> alerts:</span></p></div><p>Other equities analysts have also recently issued research reports about the stock. Weiss Ratings  reaffirmed a &#34;sell (d-)&#34; rating on shares of Spero Therapeutics in a research report on Wednesday, October 8th. Zacks Research downgraded Spero Therapeutics from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Monday, October 13th. One research analyst  has rated the stock with a Buy rating, two have given a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of &#34;Hold&#34; and a consensus target price of $5.00.</p><p><b>Check Out Our Latest Analysis on SPRO</b></p><h2>Spero Therapeutics Trading Down 0.9%</h2><p>Shares of SPRO stock opened at $2.26 on Friday. The firm has a fifty day simple moving average of $2.31 and a two-hundred day simple moving average of $2.28. Spero Therapeutics has a 12 month low of $0.51 and a 12 month high of $3.22. The firm has a market capitalization of $127.33 million, a PE ratio of -2.86 and a beta of 1.48. </p><p>Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, beating analysts' consensus estimates of ($0.25) by $0.12. The firm had revenue of $5.44 million for the quarter, compared to analyst estimates of $12.00 million. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%.  On average, equities analysts predict that  Spero Therapeutics will post -1.2 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling</h2><p>In related news, insider Esther Rajavelu sold 40,270 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $2.37, for a total value of $95,439.90. Following the sale, the insider owned 869,450 shares in the company, valued at approximately $2,060,596.50. This trade represents a 4.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own  5.50% of the company's stock. </p><h2>Institutional Investors Weigh In On Spero Therapeutics</h2><p>Large investors have recently added to or reduced their stakes in the company. Invesco Ltd. bought a new stake in  Spero Therapeutics in the 2nd quarter worth approximately $43,000.  Dimensional Fund Advisors LP bought a new position in  Spero Therapeutics during the third quarter valued at approximately $55,000.  Assenagon Asset Management S.A. purchased a new position in shares of  Spero Therapeutics during the third quarter worth approximately $70,000.  Quadrature Capital Ltd purchased a new position in shares of  Spero Therapeutics during the second quarter worth approximately $90,000.  Finally, Two Sigma Investments LP bought a new stake in shares of  Spero Therapeutics in the 3rd quarter worth approximately $93,000. Hedge funds and other institutional investors own  25.60% of the company's stock. </p><h2>Spero Therapeutics Company Profile</h2> (Get Free Report)<p>Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Spero Therapeutics</li><li>How to Choose Top Rated Stocks</li><li>Rocket Lab’s Big Rebound? Analysts Suggest the Dip's a Gift</li><li>Financial Services Stocks Investing</li><li>Meta’s AI Moment? New SAM 3 Model Has Wall Street Turning Bullish</li><li>3 Grocery Stocks That Are Proving They Are Still Essential </li><li>Snowflake Stock: The Dip That Smart Investors Are Buying Right Now</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Spero Therapeutics Right Now?</h2><p>Before you consider Spero Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Spero Therapeutics wasn't on the list.</p><p>While Spero Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

SPRO

<p>Spero Therapeutics (NASDAQ:SPRO) was downgraded by Wall Street Zen from a "buy" to "hold" rating. Other analysts also issued similar downgrades, with Weiss Ratings reaffirming a "sell" and Zacks Research downgrading to "hold." The stock opened at $2.26, with a market cap of $127.33 million. Insider Esther Rajavelu sold shares, reducing her ownership by 4.43%. Institutional investors have adjusted their stakes in the company.</p>

Spero Therapeutics (NASDAQ:SPRO) Stock Rating Lowered by Wall Street Zen